Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation (Q33406990)

26 July 2017

title

Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation (English)

1 reference

26 July 2017

Constantine S Tam

2

0 references

Hagop Kantarjian

series ordinal

3

object named as

Hagop Kantarjian

1 reference

26 July 2017

7

Srdan Verstovsek

1 reference

26 July 2017

4

Jorge Cortes

1 reference

26 July 2017

6

Raphael Pollock

1 reference

26 July 2017

Fabio P S Santos

1

1 reference

26 July 2017

Deborah Thomas

series ordinal

5

1 reference

26 July 2017

publication date

15 May 2013

1 reference

26 July 2017

1 reference

26 July 2017

volume

55

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

121-127

1 reference

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Splenectomy and chronic thromboembolic pulmonary hypertension.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Palliative splenectomy in myelofibrosis with myeloid metaplasia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Liver Dysfunction following Splenectomy in Idiopathic Myelofibrosis: A Study of 10 Patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases.

21 June 2018

1 reference

https://api.crossref.org/works/10.3109/10428194.2013.794269

International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10428194.2013.794269

Risk factors for leukemic transformation in patients with primary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10428194.2013.794269

Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/10428194.2013.794269

Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874259

Diagnostic and clinical relevance of the number of circulating CD34 cells in myelofibrosis with myeloid metaplasia

31 October 2018

1 reference

https://api.crossref.org/works/10.3109/10428194.2013.794269

Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party

21 January 2018

1 reference

12 December 2020

A note on quantifying follow-up in studies of failure time

1 reference

12 December 2020

Splenectomy in agnogenic myeloid metaplasia

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

10.3109/10428194.2013.794269

Identifiers

DOI

1 reference

26 July 2017

1 reference

26 July 2017

1 reference